Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Indaptus Therapeutics Inc (INDP)

Indaptus Therapeutics Inc (INDP)
0.6861 -0.0339 (-4.71%) 11:38 ET [NASDAQ]
0.6721 x 2 0.7000 x 10
Realtime by (Cboe BZX)
0.6721 x 2 0.7000 x 10
Realtime 0.7499 +0.0296 (-) 09:16 ET
Quote Overview for Fri, Mar 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.6400
Day High
0.7300
Open 0.7300
Previous Close 0.7200 0.7200
Volume 358,405 358,405
Avg Vol 1,061,535 1,061,535
Stochastic %K 3.43% 3.43%
Weighted Alpha -72.71 -72.71
5-Day Change -0.1423 (-17.52%) -0.1423 (-17.52%)
52-Week Range 0.6411 - 3.1000 0.6411 - 3.1000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,393
  • Shares Outstanding, K 14,429
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,020 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 1.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.95
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.24
  • Most Recent Earnings $-0.38 on 03/13/25
  • Next Earnings Date 05/14/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 1
  • High Estimate -0.41
  • Low Estimate -0.41
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +8.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6411 +4.51%
on 03/24/25
Period Open: 0.7700
1.7000 -60.59%
on 03/18/25
-0.1000 (-12.99%)
since 02/24/25
3-Month
0.6411 +4.51%
on 03/24/25
Period Open: 0.9092
1.7000 -60.59%
on 03/18/25
-0.2392 (-26.31%)
since 12/24/24
52-Week
0.6411 +4.51%
on 03/24/25
Period Open: 2.3200
3.1000 -78.39%
on 05/29/24
-1.6500 (-71.12%)
since 03/22/24

Most Recent Stories

More News
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

INDP : 0.6861 (-4.75%)
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

INDP : 0.6861 (-4.75%)
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

INDP : 0.6861 (-4.75%)
Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025

INDP : 0.6861 (-4.75%)
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

INDP : 0.6861 (-4.75%)
Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

INDP : 0.6861 (-4.75%)
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

INDP : 0.6861 (-4.75%)
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules

INDP : 0.6861 (-4.75%)
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

INDP : 0.6861 (-4.75%)
Indaptus Therapeutics Announces Securities Purchase Agreements and Private Placement for $2.135 Million

Indaptus Therapeutics announces a securities offering of 1.8 million shares and warrants, raising approximately $2.1 million for R&D.Quiver AI SummaryIndaptus Therapeutics, Inc. has announced the execution...

INDP : 0.6861 (-4.75%)

Business Summary

Indaptus Therapeutics approach is based on the hypothesis which efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals. Indaptus Therapeutics, formerly known as Intec...

See More

Key Turning Points

3rd Resistance Point 0.8034
2nd Resistance Point 0.7866
1st Resistance Point 0.7535
Last Price 0.6861
1st Support Level 0.7036
2nd Support Level 0.6868
3rd Support Level 0.6537

See More

52-Week High 3.1000
Fibonacci 61.8% 2.1607
Fibonacci 50% 1.8705
Fibonacci 38.2% 1.5804
Last Price 0.6861
52-Week Low 0.6411

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals